Minirin (Desmopressin Acetate)

Desmopressin, the active ingredient in Minirin, is a vasopressin analog presented as an oral tablet for oral use. It treats central diabetes insipidus, nocturnal enuresis, primary nocturnal polyuria and helps control bleeding episodes in patients with hemophilia A.

GNH USA supplies Minirin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Desmopressin acts on the antidiuretic pathway to reduce excessive urine output and manage bleeding disorders.

- Central diabetes insipidus: restores water balance by reducing polyuria. - Nocturnal enuresis: decreases nighttime urine production, improving sleep continuity. - Primary nocturnal polyuria: lowers nocturnal urine volume, reducing bedwetting episodes. - Hemophilia A (bleeding episodes): raises plasma factor VIII levels to aid haemostatic control.

Desmopressin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional, often transient. - Nasal congestion: when administered intranasally. - Abdominal discomfort: mild cramping or pain. - Mild hyponatraemia: slight reduction in serum sodium.

Serious or Rare Side Effects: - Severe hyponatraemia: can lead to confusion, seizures, or coma. - Water intoxication: excessive fluid retention causing cerebral oedema. - Allergic reactions: rash, itching, or anaphylaxis in rare cases. - Thromboembolic events: rare clot formation in predisposed individuals.

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor relevant parameters.

- Fluid intake monitoring: advise patients to limit excessive water consumption. - Serum sodium assessment: check baseline and periodic sodium levels. - Renal function evaluation: adjust use in patients with impaired kidney function. - Concomitant drug review: avoid drugs that promote hyponatraemia. - Elderly dosing caution: start with the lowest effective dose. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Desmopressin may interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - MAO inhibitors: increase risk of severe hyponatraemia. - Carbamazepine: reduces desmopressin effectiveness. - Conivaptan: antagonises V2‑receptor activity.

Moderate Interactions (Monitor Closely): - NSAIDs: may potentiate water retention and hyponatraemia. - Loop diuretics: can exacerbate electrolyte disturbances. - SSRIs: modestly increase hyponatraemia risk. - Antihypertensives: may enhance antidiuretic effect, requiring blood pressure monitoring.